Do analysts recommend LTRN or CTOR?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lantern Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Citius Oncology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings and valuation, LTRN or CTOR?

Citius Oncology is trading at a lower price-to-earnings ratio than Lantern Pharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Lantern Pharma N/A N/A -$17.12M -$1.62 N/A Citius Oncology N/A N/A -$24.76M -$0.47 N/A

Is LTRN or CTOR more profitable?

Citius Oncology's return on equity of -102.98% beat Lantern Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Lantern Pharma N/A -368.02% -148.62% Citius Oncology N/A -102.98% -43.49%

Do analysts prefer LTRN or ACRV?

Acrivon Therapeutics has a consensus price target of $13.50, suggesting a potential upside of 555.34%. Given Acrivon Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Acrivon Therapeutics is more favorable than Lantern Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lantern Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Acrivon Therapeutics 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50

Which has better valuation and earnings, LTRN or ACRV?

Acrivon Therapeutics is trading at a lower price-to-earnings ratio than Lantern Pharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Lantern Pharma N/A N/A -$17.12M -$1.62 N/A Acrivon Therapeutics N/A N/A -$77.90M -$1.88 N/A

Is LTRN or ACRV more profitable?

Acrivon Therapeutics' return on equity of -70.14% beat Lantern Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Lantern Pharma N/A -368.02% -148.62% Acrivon Therapeutics N/A -70.14% -61.60%

Does the media prefer LTRN or ACRV?

In the previous week, Lantern Pharma had 1 more articles in the media than Acrivon Therapeutics. MarketBeat recorded 5 mentions for Lantern Pharma and 4 mentions for Acrivon Therapeutics. Acrivon Therapeutics' average media sentiment score of 0.29 beat Lantern Pharma's score of 0.23 indicating that Acrivon Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lantern Pharma 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Acrivon Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend LTRN or TELO?

Telomir Pharmaceuticals has a consensus price target of $4.00, suggesting a potential upside of 227.87%. Given Telomir Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Telomir Pharmaceuticals is more favorable than Lantern Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lantern Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Telomir Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Which has preferable valuation and earnings, LTRN or TELO?

Telomir Pharmaceuticals is trading at a lower price-to-earnings ratio than Lantern Pharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Lantern Pharma N/A N/A -$17.12M -$1.62 N/A Telomir Pharmaceuticals N/A N/A -$10.41M -$0.91 N/A

Is LTRN or TELO more profitable?

Telomir Pharmaceuticals' return on equity of -102.70% beat Lantern Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Lantern Pharma N/A -368.02% -148.62% Telomir Pharmaceuticals N/A -102.70% -90.75%

Does the media prefer LTRN or TELO?

In the previous week, Telomir Pharmaceuticals had 1 more articles in the media than Lantern Pharma. MarketBeat recorded 6 mentions for Telomir Pharmaceuticals and 5 mentions for Lantern Pharma. Lantern Pharma's average media sentiment score of 0.23 beat Telomir Pharmaceuticals' score of 0.00 indicating that Lantern Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lantern Pharma 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Telomir Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend LTRN or SERA?

Sera Prognostics has a consensus price target of $5.50, indicating a potential upside of 166.99%. Given Sera Prognostics' stronger consensus rating and higher possible upside, analysts plainly believe Sera Prognostics is more favorable than Lantern Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lantern Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Sera Prognostics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.67

Does the media refer more to LTRN or SERA?

In the previous week, Lantern Pharma had 4 more articles in the media than Sera Prognostics. MarketBeat recorded 5 mentions for Lantern Pharma and 1 mentions for Sera Prognostics. Lantern Pharma's average media sentiment score of 0.23 beat Sera Prognostics' score of 0.00 indicating that Lantern Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lantern Pharma 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Sera Prognostics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher earnings and valuation, KLRS or LTRN?

Kalaris Therapeutics is trading at a lower price-to-earnings ratio than Lantern Pharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Kalaris Therapeutics N/A N/A -$43.44M -$2.02 N/A Lantern Pharma N/A N/A -$17.12M -$1.62 N/A

Is KLRS or LTRN more profitable?

Kalaris Therapeutics' return on equity of -71.71% beat Lantern Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Kalaris Therapeutics N/A -71.71% -42.95% Lantern Pharma N/A -368.02% -148.62%

Lantern Pharma (LTRN) Competitors

$1.39 +0.03 (+2.21%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$1.38 -0.01 (-1.08%)

As of 09/23/2026 07:45 PM Eastern

Compare

LTRN vs. CTOR, ACRV, TELO, SERA, and KLRS

Should you buy Lantern Pharma stock or one of its competitors? Lantern Pharma's main competitors and comparable companies include Citius Oncology (CTOR), Acrivon Therapeutics (ACRV), Telomir Pharmaceuticals (TELO), Sera Prognostics (SERA), and Kalaris Therapeutics (KLRS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Lantern Pharma compare to Citius Oncology?

Lantern Pharma (NASDAQ:LTRN) and Citius Oncology (NASDAQ:CTOR) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, dividends, institutional ownership, analyst recommendations, earnings and profitability.

Citius Oncology's return on equity of -102.98% beat Lantern Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lantern Pharma	N/A	-368.02%	-148.62%
Citius Oncology	N/A	-102.98%	-43.49%

28.6% of Lantern Pharma shares are owned by institutional investors. Comparatively, 70.5% of Citius Oncology shares are owned by institutional investors. 8.5% of Lantern Pharma shares are owned by insiders. Comparatively, 9.8% of Citius Oncology shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lantern Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Citius Oncology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Lantern Pharma had 5 more articles in the media than Citius Oncology. MarketBeat recorded 5 mentions for Lantern Pharma and 0 mentions for Citius Oncology. Lantern Pharma's average media sentiment score of 0.23 beat Citius Oncology's score of 0.00 indicating that Lantern Pharma is being referred to more favorably in the media.

Company	Overall Sentiment
Lantern Pharma	Neutral
Citius Oncology	Neutral

Citius Oncology is trading at a lower price-to-earnings ratio than Lantern Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lantern Pharma	N/A	N/A	-$17.12M	-$1.62	N/A
Citius Oncology	N/A	N/A	-$24.76M	-$0.47	N/A

Lantern Pharma has a beta of 2.3, indicating that its share price is 130% more volatile than the broader market. Comparatively, Citius Oncology has a beta of 3.52, indicating that its share price is 252% more volatile than the broader market.

Summary

Citius Oncology beats Lantern Pharma on 6 of the 10 factors compared between the two stocks.

How does Lantern Pharma compare to Acrivon Therapeutics?

Lantern Pharma (NASDAQ:LTRN) and Acrivon Therapeutics (NASDAQ:ACRV) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, institutional ownership, dividends, media sentiment and earnings.

Acrivon Therapeutics' return on equity of -70.14% beat Lantern Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lantern Pharma	N/A	-368.02%	-148.62%
Acrivon Therapeutics	N/A	-70.14%	-61.60%

Acrivon Therapeutics is trading at a lower price-to-earnings ratio than Lantern Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lantern Pharma	N/A	N/A	-$17.12M	-$1.62	N/A
Acrivon Therapeutics	N/A	N/A	-$77.90M	-$1.88	N/A

Acrivon Therapeutics has a consensus price target of $13.50, suggesting a potential upside of 555.34%. Given Acrivon Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Acrivon Therapeutics is more favorable than Lantern Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lantern Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Acrivon Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

28.6% of Lantern Pharma shares are owned by institutional investors. Comparatively, 71.6% of Acrivon Therapeutics shares are owned by institutional investors. 8.5% of Lantern Pharma shares are owned by insiders. Comparatively, 10.5% of Acrivon Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Lantern Pharma had 1 more articles in the media than Acrivon Therapeutics. MarketBeat recorded 5 mentions for Lantern Pharma and 4 mentions for Acrivon Therapeutics. Acrivon Therapeutics' average media sentiment score of 0.29 beat Lantern Pharma's score of 0.23 indicating that Acrivon Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lantern Pharma	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Acrivon Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Lantern Pharma has a beta of 2.3, suggesting that its stock price is 130% more volatile than the broader market. Comparatively, Acrivon Therapeutics has a beta of 1.92, suggesting that its stock price is 92% more volatile than the broader market.

Summary

Acrivon Therapeutics beats Lantern Pharma on 8 of the 13 factors compared between the two stocks.

How does Lantern Pharma compare to Telomir Pharmaceuticals?

Lantern Pharma (NASDAQ:LTRN) and Telomir Pharmaceuticals (NASDAQ:TELO) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, institutional ownership, earnings, profitability, valuation and risk.

Telomir Pharmaceuticals is trading at a lower price-to-earnings ratio than Lantern Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lantern Pharma	N/A	N/A	-$17.12M	-$1.62	N/A
Telomir Pharmaceuticals	N/A	N/A	-$10.41M	-$0.91	N/A

In the previous week, Telomir Pharmaceuticals had 1 more articles in the media than Lantern Pharma. MarketBeat recorded 6 mentions for Telomir Pharmaceuticals and 5 mentions for Lantern Pharma. Lantern Pharma's average media sentiment score of 0.23 beat Telomir Pharmaceuticals' score of 0.00 indicating that Lantern Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lantern Pharma	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Telomir Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Lantern Pharma has a beta of 2.3, meaning that its stock price is 130% more volatile than the broader market. Comparatively, Telomir Pharmaceuticals has a beta of -0.25, meaning that its stock price is 125% less volatile than the broader market.

Telomir Pharmaceuticals has a consensus price target of $4.00, suggesting a potential upside of 227.87%. Given Telomir Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Telomir Pharmaceuticals is more favorable than Lantern Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lantern Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Telomir Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

28.6% of Lantern Pharma shares are held by institutional investors. 8.5% of Lantern Pharma shares are held by insiders. Comparatively, 16.4% of Telomir Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Telomir Pharmaceuticals' return on equity of -102.70% beat Lantern Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lantern Pharma	N/A	-368.02%	-148.62%
Telomir Pharmaceuticals	N/A	-102.70%	-90.75%

Summary

Telomir Pharmaceuticals beats Lantern Pharma on 9 of the 13 factors compared between the two stocks.

How does Lantern Pharma compare to Sera Prognostics?

Lantern Pharma (NASDAQ:LTRN) and Sera Prognostics (NASDAQ:SERA) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, media sentiment, earnings, institutional ownership, dividends, analyst recommendations, valuation and risk.

Lantern Pharma has a net margin of 0.00% compared to Sera Prognostics' net margin of -47,475.72%. Sera Prognostics' return on equity of -46.71% beat Lantern Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lantern Pharma	N/A	-368.02%	-148.62%
Sera Prognostics	-47,475.72%	-46.71%	-34.06%

Lantern Pharma has a beta of 2.3, suggesting that its share price is 130% more volatile than the broader market. Comparatively, Sera Prognostics has a beta of 0.98, suggesting that its share price is 2% less volatile than the broader market.

Lantern Pharma has higher earnings, but lower revenue than Sera Prognostics. Sera Prognostics is trading at a lower price-to-earnings ratio than Lantern Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lantern Pharma	N/A	N/A	-$17.12M	-$1.62	N/A
Sera Prognostics	$80K	1,015.84	-$31.93M	-$0.67	N/A

In the previous week, Lantern Pharma had 4 more articles in the media than Sera Prognostics. MarketBeat recorded 5 mentions for Lantern Pharma and 1 mentions for Sera Prognostics. Lantern Pharma's average media sentiment score of 0.23 beat Sera Prognostics' score of 0.00 indicating that Lantern Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lantern Pharma	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Sera Prognostics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

28.6% of Lantern Pharma shares are owned by institutional investors. Comparatively, 54.6% of Sera Prognostics shares are owned by institutional investors. 8.5% of Lantern Pharma shares are owned by company insiders. Comparatively, 11.3% of Sera Prognostics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Sera Prognostics has a consensus price target of $5.50, indicating a potential upside of 166.99%. Given Sera Prognostics' stronger consensus rating and higher possible upside, analysts plainly believe Sera Prognostics is more favorable than Lantern Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lantern Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Sera Prognostics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

Summary

Sera Prognostics beats Lantern Pharma on 10 of the 16 factors compared between the two stocks.

How does Lantern Pharma compare to Kalaris Therapeutics?

Kalaris Therapeutics (NASDAQ:KLRS) and Lantern Pharma (NASDAQ:LTRN) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, profitability, risk, analyst recommendations, institutional ownership and media sentiment.

Kalaris Therapeutics currently has a consensus price target of $18.75, indicating a potential upside of 500.96%. Given Kalaris Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Kalaris Therapeutics is more favorable than Lantern Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kalaris Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Lantern Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Kalaris Therapeutics has a beta of 0.22, meaning that its stock price is 78% less volatile than the broader market. Comparatively, Lantern Pharma has a beta of 2.3, meaning that its stock price is 130% more volatile than the broader market.

In the previous week, Lantern Pharma had 5 more articles in the media than Kalaris Therapeutics. MarketBeat recorded 5 mentions for Lantern Pharma and 0 mentions for Kalaris Therapeutics. Lantern Pharma's average media sentiment score of 0.23 beat Kalaris Therapeutics' score of 0.00 indicating that Lantern Pharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Kalaris Therapeutics	Neutral
Lantern Pharma	Neutral

66.1% of Kalaris Therapeutics shares are owned by institutional investors. Comparatively, 28.6% of Lantern Pharma shares are owned by institutional investors. 68.1% of Kalaris Therapeutics shares are owned by company insiders. Comparatively, 8.5% of Lantern Pharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Kalaris Therapeutics' return on equity of -71.71% beat Lantern Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kalaris Therapeutics	N/A	-71.71%	-42.95%
Lantern Pharma	N/A	-368.02%	-148.62%

Kalaris Therapeutics is trading at a lower price-to-earnings ratio than Lantern Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kalaris Therapeutics	N/A	N/A	-$43.44M	-$2.02	N/A
Lantern Pharma	N/A	N/A	-$17.12M	-$1.62	N/A

Summary

Kalaris Therapeutics beats Lantern Pharma on 7 of the 13 factors compared between the two stocks.

Get Lantern Pharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LTRN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LTRN vs. The Competition

Export

Metric	Lantern Pharma	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$17.39M	$3.98B	$7.32B	$13.29B
Dividend Yield	N/A	3.63%	2.52%	12.57%
P/E Ratio	-0.86	13.88	274.01	25.69
Price / Sales	N/A	1,411.37	667.24	93.60
Price / Cash	N/A	113.29	77.80	52.76
Price / Book	2.40	15.30	10.44	6.32
Net Income	-$17.12M	-$22.82M	$3.49B	$359.73M
7 Day Performance	-27.98%	-0.22%	0.51%	1.35%
1 Month Performance	-40.60%	-6.06%	-3.38%	-3.68%
1 Year Performance	-65.85%	34.37%	16.04%	5.56%

Lantern Pharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LTRN Lantern Pharma	0.6987 of 5 stars	$1.39 +2.2%	N/A	-65.8%	$17.39M	N/A	N/A	16	News Coverage
CTOR Citius Oncology	0.11 of 5 stars	$0.86 -8.9%	$6.00 +600.9%	-44.2%	$87.40M	N/A	N/A	N/A	Positive News High Trading Volume
ACRV Acrivon Therapeutics	3.8297 of 5 stars	$1.83 -6.6%	$13.50 +637.7%	+30.4%	$83.99M	N/A	N/A	58	Positive News
TELO Telomir Pharmaceuticals	1.537 of 5 stars	$1.17 flat	N/A	-19.7%	$80.47M	N/A	N/A	1
SERA Sera Prognostics	1.9043 of 5 stars	$1.99 -0.5%	$5.50 +176.4%	-33.3%	$78.90M	$80K	N/A	120

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LTRN) was last updated on 9/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Lantern Pharma (LTRN) Competitors

LTRN vs. CTOR, ACRV, TELO, SERA, and KLRS

How does Lantern Pharma compare to Citius Oncology?

Summary

How does Lantern Pharma compare to Acrivon Therapeutics?

Summary

How does Lantern Pharma compare to Telomir Pharmaceuticals?

Summary

How does Lantern Pharma compare to Sera Prognostics?

Summary

How does Lantern Pharma compare to Kalaris Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LTRN vs. The Competition

Lantern Pharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Lantern Pharma (LTRN) Competitors

LTRN vs. CTOR, ACRV, TELO, SERA, and KLRS

How does Lantern Pharma compare to Citius Oncology?

Is LTRN or CTOR more profitable?

Do insiders and institutionals have more ownership in LTRN or CTOR?

Do analysts recommend LTRN or CTOR?

Does the media favor LTRN or CTOR?

Which has preferable earnings and valuation, LTRN or CTOR?

Which has more volatility and risk, LTRN or CTOR?

Summary

How does Lantern Pharma compare to Acrivon Therapeutics?

Is LTRN or ACRV more profitable?

Which has better valuation and earnings, LTRN or ACRV?

Do analysts prefer LTRN or ACRV?

Do institutionals & insiders hold more shares of LTRN or ACRV?

Does the media prefer LTRN or ACRV?

Which has more volatility and risk, LTRN or ACRV?

Summary

How does Lantern Pharma compare to Telomir Pharmaceuticals?

Which has preferable valuation and earnings, LTRN or TELO?

Does the media prefer LTRN or TELO?

Which has more risk & volatility, LTRN or TELO?

Do analysts recommend LTRN or TELO?

Do insiders and institutionals hold more shares of LTRN or TELO?

Is LTRN or TELO more profitable?

Summary

How does Lantern Pharma compare to Sera Prognostics?

Is LTRN or SERA more profitable?

Which has more risk & volatility, LTRN or SERA?

Which has stronger earnings and valuation, LTRN or SERA?

Does the media refer more to LTRN or SERA?

Do institutionals & insiders have more ownership in LTRN or SERA?

Do analysts recommend LTRN or SERA?

Summary

How does Lantern Pharma compare to Kalaris Therapeutics?

Do analysts rate KLRS or LTRN?

Which has more volatility & risk, KLRS or LTRN?

Does the media refer more to KLRS or LTRN?

Do institutionals & insiders have more ownership in KLRS or LTRN?

Is KLRS or LTRN more profitable?

Which has higher earnings and valuation, KLRS or LTRN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LTRN vs. The Competition

Lantern Pharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools